The Life Sciences team represented Repligen Corporation (NASDAQ:RGEN) in its pending acquisition of privately held Spectrum, Inc. for approximately $359 million, comprised of $120 million in cash plus 6,154,000 shares of Repligen stock. To fund the transaction, Repligen intends to use its $142 million cash on hand and potentially a committed debt financing of $30 million that it has obtained from JPMorgan Chase & Co.
The addition of Spectrum is expected to accelerate the growth of Repligen’s filtration business, provide access to new customers, and greatly expand its commercial footprint, strengthening Repligen’s position as a leader in single-use and continuous manufacturing technologies for bioprocessing.
Repligen Corporation is a bioprocessing company focused on the development, manufacture and commercialization of highly innovative products used to manufacture biologic drugs. The company’s bioprocessing products are sold to major life sciences companies, biopharmaceutical development companies and contract manufacturing organizations worldwide.
The Goodwin team was led by partners Jason Breen and Arthur McGivern, associates Courtney Gaughan and Gabriela Morales-Rivera and included partners Janet Andolina, Gregory Bibler, Jennifer Bralower, Brian Fairchild, Jennifer Fay, Richard Matheny and James Mattus, counsel J. Todd Hahn and Kirby Lewis, and associates Yuan Gao, Timothy Holahan, Victoria Kahn, Ananth Lakshman, Jacob Osborn, Alexander Plaum, Brenna Moorhead and Juliet Rognlie and summer associate James Nikraftar.
For additional details on the agreement, please read the press release.